CEACAM5, CEA cell adhesion molecule 5, 1048

N. diseases: 428; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE While CEA protein concentrations in lung cell lines were similar to those present in G1 cell lines, the ratio of NCA:CEA RNA was significantly higher in lung cancer lines than in colorectal lines. 1330929 1992
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE CEA mRNA was detected together with NCA mRNA in nine cultured cell lines, with the exception of the lung carcinoma A549 cell line, and in 19 colon tissue specimens, including carcinomas, adjacent noninvaded tissues and adenomas. 2067130 1991
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE CEA content in non-carcinomatous lung tissue was increased in smokers with emphysema (mean (SD) 38.0 (9.2) ng/mg protein) or with lung cancer (38.2 (21.6)) compared with non-smokers (11.0 (5.4)) or ex-smokers (5.9 (2.2)). 7638808 1995
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE These findings suggest that NCA is a major member of the CEA-related gene family expressed in lung cancer. 7678982 1993
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. 7923150 1994
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE A combined assay using both ADAM8 and carcinoembryonic antigen increased sensitivity because 80% of the lung cancer patients were then diagnosed as positive, whereas only 11% of 72 healthy volunteers were falsely diagnosed as positive. 15623614 2004
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Numerous potential DNA biomarkers such as hypermethylations of the promoters and mutations in K-ras, p53, and protein biomarkers; carcinoembryonic antigen (CEA), CYFRA21-1, plasma kallikrein B1 (KLKB1), Neuron-specific enolase, etc. have been discovered as lung cancer biomarkers. 18823584 2008
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Our result suggests that gene therapy using pCEA-TK/CD may be a promising new approach for treating lung cancer. 22099873 2012
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE The sensitivities of those markers for lung cancer detection were respectively 39.0%, 53.7%, and 34.1% at 94.9% specificity, and the cutoff levels at those sensitivities and specificities were 4.5 ng/mL for CYFRA 21-1, 5.4 ng/mL for CEA, and 2.7 U/mL for anti-p53. 22129186 2011
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Two tests in lung cancer (ERCC1 and EGFR) and 1 test in breast cancer (CEA/CA15-3/CA27.29) were identified as top research priorities. 22274803 2012
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions. 24072496 2014
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 GeneticVariation disease BEFREE For the diagnosis of malignant pleural effusion caused by lung cancer, LUNX mRNA exhibited higher sensitivity (80%), when compared with vascular endothelial growth factor mRNA (65%), carcinoembryonic antigen (67%) and Cyfra21-1 (61%), with the same specificity (95%). 25425729 2014
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Compared with the traditional lung cancer diagnostic biomarkers carcinoembryonic antigen and cytokeratin 19 fragment, GpAEA and sphingosine were as good or more appropriate for detecting lung cancer. 25961003 2015
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE There were significant differences between the peripheral lung cancer group and the benign lung disease group (P < 0.05) in the serum of HSP90α and CEA.There were no differences in others. 26260621 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE About 37.5% of carcinoembryonic antigen (CEA)-negative lung cancer patients were CR-1 positive at 95% specificity. 26605871 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Furthermore, the recovery of carcinoembryonic antigen to pre-radiation levels was more rapid in lung cancer patients with high levels of HIF-2α expression, and these patients had shorter survival times (P = 0.018). 26782458 2015
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer. 27080225 2016
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE A novel quantum dot-doped polystyrene nanoparticles-based lateral flow test strips (QPs-LFTS) system was developed to simultaneously detect a cytokeratin-19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) in human serum to aid the diagnosis and prognosis of lung cancer. 27988480 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Assay of multiple serum tumor markers such as carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen (CYFRA21-1), and neuron specific enolase (NSE), is important for the early diagnosis of lung cancer. 28110687 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE A classification rule based on EGF, sCD26, Calprotectin and CEA was established, able to reasonably discriminate lung cancer with 97% sensitivity and 43% specificity in the training set, and 91.7% sensitivity and 45.4% specificity in the validation set. 28117344 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE The roles of carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA21-1) and neuron-specific enolase (NSE) in metastases occurrence and poor diagnosis in specific histological classifications of lung cancer need further exploring. 28152979 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE In this review, we discuss the molecular features, functions, and clinical relevance of the conventional serum biomarkers for lung cancer, including carcinoembryonic antigen (CEA), cytokeratin 19 fragment 21-1 (CYFRA 21-1), tissue polypeptide antigen (TPA), carbohydrate antigen 19-9 (CA19-9), sialyl Lewis<sup>x</sup> (sLe<sup>x</sup>), carbohydrate antigen 125 (CA-125), squamous cell carcinoma-related antigen (SCC-Ag), neuron-specific enolase (NSE), and pro-gastrin-releasing peptide (proGRP), aiming to provide a snapshot of the current landscape and their potential combined utility in the diagnosis and prognosis of lung cancer. 28229299 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE CEA, a lung cancer protein biomarker, was used as analyte to demonstrate the principle of the immunochromatographic assay on cotton thread biosensor. 28411630 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Small lung lesions, advanced pathological stage, adjuvant chemotherapy after CRC surgery, solitary pulmonary lesions with lower border irregularity, higher carcinoembryonic antigen level, and the lack of concomitant mediastinal lymph node metastasis were more likely to be associated with pulmonary metastasis than with primary lung cancer. 28487728 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE At 90% specificity, the panel of MIC-1, Cyfra21-1, CA125 and CEA provided 89.5% sensitivity for early diagnosis of lung cancer, which could be used to concentrate the high-risk subjects for further LDCT screening. 28514755 2017